Sarah E Cusick1, Robert O Opoka2, Andrew S Ssemata2, Michael K Georgieff3, Chandy C John3. 1. Department of Pediatrics, University of Minnesota School of Medicine, Minneapolis, MN; and scusick@umn.edu. 2. Department of Paediatrics and Child Health, Makerere University College of Health Sciences, Kampala, Uganda. 3. Department of Pediatrics, University of Minnesota School of Medicine, Minneapolis, MN; and.
Abstract
BACKGROUND: The provision of iron with antimalarial treatment is the standard of care for concurrent iron deficiency and malaria. However, iron that is given during a malaria episode may not be well absorbed or used, particularly in children with severe malaria and profound inflammation. OBJECTIVES: We aimed to 1) determine baseline values of iron and inflammatory markers in children with severe malarial anemia (SMA), children with cerebral malaria (CM), and community children (CC) and 2) compare markers in iron-deficient children in each group who received 28 d of iron supplementation during antimalarial treatment with those in children who did not receive iron during treatment.. DESIGN: Seventy-nine children with CM, 77 children with SMA, and 83 CC who presented to Mulago Hospital, Kampala, Uganda, were enrolled in a 28-d iron-therapy study. Children with malaria received antimalarial treatment. All children with CM or SMA, as well as 35 CC, had zinc protoporphyrin (ZPP) concentrations ≥80 μmol/mol heme and were randomly assigned to receive a 28-d course of iron or no iron. We compared iron markers at day 0 among study groups (CM, SMA, and CC groups) and at day 28 between children in each group who were randomly assigned to receive iron or to not receive iron. RESULTS: At day 0, children with CM and SMA had greater values of C-reactive protein, ferritin, and hepcidin than those of CC. At day 28, interactions between study and treatment group were NS. Children in the no-iron compared with iron groups had similar mean values for hemoglobin (115 compared with 113 g/L, respectively; P = 0.73) and ZPP (124 compared with 124 μmol/mol heme, respectively; P = 0.96) but had lower median ferritin [101.0 μg/L (95% CI: 84.2, 121.0 μg/L) compared with 152.9 μg/L (128.8, 181.6 μg/L), respectively; P ≤ 0.001] and hepcidin [45.8 ng/mL (36.8, 56.9 ng/mL) compared with 83.1 ng/mL (67.6, 102.2 ng/mL), respectively; P < 0.011]. CONCLUSIONS: Severe inflammation is a characterization of children with CM and SMA. The withholding of iron from children with severe malaria is associated with lower ferritin and hepcidin at day 28 but not a lower hemoglobin concentration. This trial was registered at clinicaltrials.gov as NCT01093989.
RCT Entities:
BACKGROUND: The provision of iron with antimalarial treatment is the standard of care for concurrent iron deficiency and malaria. However, iron that is given during a malaria episode may not be well absorbed or used, particularly in children with severe malaria and profound inflammation. OBJECTIVES: We aimed to 1) determine baseline values of iron and inflammatory markers in children with severe malarial anemia (SMA), children with cerebral malaria (CM), and community children (CC) and 2) compare markers in iron-deficient children in each group who received 28 d of iron supplementation during antimalarial treatment with those in children who did not receive iron during treatment.. DESIGN: Seventy-nine children with CM, 77 children with SMA, and 83 CC who presented to Mulago Hospital, Kampala, Uganda, were enrolled in a 28-d iron-therapy study. Children with malaria received antimalarial treatment. All children with CM or SMA, as well as 35 CC, had zinc protoporphyrin (ZPP) concentrations ≥80 μmol/mol heme and were randomly assigned to receive a 28-d course of iron or no iron. We compared iron markers at day 0 among study groups (CM, SMA, and CC groups) and at day 28 between children in each group who were randomly assigned to receive iron or to not receive iron. RESULTS: At day 0, children with CM and SMA had greater values of C-reactive protein, ferritin, and hepcidin than those of CC. At day 28, interactions between study and treatment group were NS. Children in the no-iron compared with iron groups had similar mean values for hemoglobin (115 compared with 113 g/L, respectively; P = 0.73) and ZPP (124 compared with 124 μmol/mol heme, respectively; P = 0.96) but had lower median ferritin [101.0 μg/L (95% CI: 84.2, 121.0 μg/L) compared with 152.9 μg/L (128.8, 181.6 μg/L), respectively; P ≤ 0.001] and hepcidin [45.8 ng/mL (36.8, 56.9 ng/mL) compared with 83.1 ng/mL (67.6, 102.2 ng/mL), respectively; P < 0.011]. CONCLUSIONS: Severe inflammation is a characterization of children with CM and SMA. The withholding of iron from children with severe malaria is associated with lower ferritin and hepcidin at day 28 but not a lower hemoglobin concentration. This trial was registered at clinicaltrials.gov as NCT01093989.
Authors: Quirijn de Mast; Behzad Nadjm; Hugh Reyburn; Erwin H J M Kemna; Ben Amos; Coby M M Laarakkers; Simphorosa Silalye; Hans Verhoef; Robert W Sauerwein; Dorine W Swinkels; Andre J A M van der Ven Journal: J Infect Dis Date: 2009-01-15 Impact factor: 5.226
Authors: Anne E P Frosch; Bartholomew N Ondigo; George A Ayodo; John M Vulule; Chandy C John; Sarah E Cusick Journal: Am J Clin Nutr Date: 2014-07-30 Impact factor: 7.045
Authors: Hans Verhoef; Clive E West; Silas M Nzyuko; Stefan de Vogel; Rikkert van der Valk; Mike A Wanga; Anneleen Kuijsten; Jacobien Veenemans; Frans J Kok Journal: Lancet Date: 2002-09-21 Impact factor: 79.321
Authors: Dominik Glinz; Richard F Hurrell; Mamadou Ouattara; Michael B Zimmermann; Gary M Brittenham; Lukas G Adiossan; Aurélie A Righetti; Burkhardt Seifert; Victorine G Diakité; Jürg Utzinger; Eliézer K N'Goran; Rita Wegmüller Journal: Malar J Date: 2015-09-17 Impact factor: 2.979
Authors: Sant-Rayn Pasricha; Sarah H Atkinson; Andrew E Armitage; Shivani Khandwala; Jacobien Veenemans; Sharon E Cox; Lucy A Eddowes; Theodore Hayes; Conor P Doherty; Ayse Y Demir; Edwin Tijhaar; Hans Verhoef; Andrew M Prentice; Hal Drakesmith Journal: Sci Transl Med Date: 2014-05-07 Impact factor: 17.956
Authors: Conor P Doherty; Sharon E Cox; Antony J Fulford; Steven Austin; David C Hilmers; Steven A Abrams; Andrew M Prentice Journal: PLoS One Date: 2008-05-07 Impact factor: 3.240
Authors: Dominik Glinz; Moses Kamiyango; Kamija S Phiri; Francis Munthali; Christophe Zeder; Michael B Zimmermann; Richard F Hurrell; Rita Wegmüller Journal: Malar J Date: 2014-10-10 Impact factor: 2.979
Authors: Sarah E Cusick; Robert O Opoka; Steven A Abrams; Chandy C John; Michael K Georgieff; Ezekiel Mupere Journal: J Nutr Date: 2016-06-29 Impact factor: 4.798
Authors: John Mbaziira Ssenkusu; James Steven Hodges; Robert Opika Opoka; Richard Idro; Elsa Shapiro; Chandy Chiramukhathu John; Paul Bangirana Journal: Pediatrics Date: 2016-10-05 Impact factor: 7.124
Authors: Sarah E Cusick; Robert O Opoka; Andrew S Ssemata; Michael K Georgieff; Chandy C John Journal: Am J Clin Nutr Date: 2020-05-01 Impact factor: 8.472
Authors: Andrew S Ssemata; Meredith Hickson; John M Ssenkusu; Sarah E Cusick; Noeline Nakasujja; Robert O Opoka; Maria Kroupina; Michael K Georgieff; Paul Bangirana; Chandy C John Journal: Pediatr Res Date: 2020-05-13 Impact factor: 3.756